Author:
Candelaria M.,Gallardo-Rincón D.,Arce C.,Cetina L.,Aguilar-Ponce J.L.,Arrieta Ó,González-Fierro A.,Chávez-Blanco A.,de la Cruz-Hernández E.,Camargo M.F.,Trejo-Becerril C.,Pérez-Cárdenas E.,Pérez-Plasencia C.,Taja-Chayeb L.,Wegman-Ostrosky T.,Revilla-Vazquez A.,Dueñas-González A.
Reference42 articles.
1. Epigenetics as a mechanism driving polygenic clinical drug resistance;Glasspool;Br J Cancer,2006
2. Can the state of cancer chemotherapy resistance be reverted by epigenetic therapy?;Pérez-Plasencia;Mol Cancer,2006
3. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity;Cornacchia;J Immunol,1988
4. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy;Segura-Pacheco;Clin Cancer Res,2003
5. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine;Chuang;Mol Cancer Ther,2005
Cited by
212 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献